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Drosophila Toll was initially discovered as the factor respon-
sible for determining dorsoventral polarity in Drosophila
embryo, and the subsequent studies revealed its antifungal
functions. In the late 1990s, mammalian homologs of
Toll were determined as Toll-like receptors (TLRs). Early
studies on TLRs attempted to identify their specific ligands,
new family member of TLRs, and their intracellular signal
transduction pathways. Intracellular signal transductions of
TLRs share common elements with IL-1 receptor down-
stream intracellular signaling. Subsequent studies for TLRs
have focused on infectious diseases, since TLRs recog-
nize pathogen-associated molecular patterns (PAMPs) and
induce strong responses for host defense. Recently, endoge-
nous TLR ligands released from dying and/or damaged cells
were identified. These studies have extended the idea that
TLR signaling is also activated in the absence of exogenous
pathogens and in general sense “danger signals” to alert the
host of either exogenous or endogenous “danger.”
Liver has a unique anatomy that is closely associated
with the intestines through the portal vein and bile ducts.
Even when intestinal barrier functions are intact, liver is
constantly exposed to low levels of microbial products
derived from commensal microflora through portal vein
blood. Liver contains not only parenchymal hepatocytes,
but also nonparenchymal immune cells and nonimmune
cells. Hepatic immune cells include Kupﬀer cells (resident
liver tissue macrophages), T cells, B cells, dendritic cells,
NK cells, and NKT cells. These cells produce a broad array
of cytokines upon activation of TLRs. nonimmune cells in
the liver include endothelial cells, biliary epithelial cells, and
hepatic stellate cells. Hepatic nonimmune cells also express
TLRs and respond to TLR ligands to induce innate immune
responses including cytokine and type I IFN production.
However, the liver in normal condition prevents spontaneous
inflammation induced by microbial products through TLRs
due to the specific barrier functions in the liver and
intestines or the “liver tolerance” regulated by intercellular
and intracellular mechanisms. Upon breakdown of this
regulation, inflammation is induced through innate immune
responses including TLR signaling in the liver. Moreover,
sterile inflammation-associated danger signals may also
trigger liver inflammation through TLRs. Thus, acute and
chronic liver diseases are highly associated with triggering
TLR signaling by intestine-derived microbial products and
sterile insult-associated products from damaged cells.
In the present special issue of Toll-Like Receptor Signaling
in Liver Diseases, the most recent advances in TLR research
in the liver are reviewed by worldwide authorities of liver
TLR research. The first part of this issue overviews TLR
signaling in general. In the first paper, Drs. M. Yamamoto
and K. Takeda reviews the current views of TLR signaling
including their discovery of the functions of all four TLR
adaptor proteins by generating knockout mice. In the second
paper, Drs. A. E. Bigorgne and I. N. Crispe review the
area of hepatic intercellular crosstalk mediated by TLRs. In
the third paper, the research group of Drs. M. Fujimoto
and T. Naka have cloned SOCS-1 and reported that SOCS-
1 negatively regulates TLR signaling by SOCS-1. They
summarize the negative regulation of TLRs by SOCS proteins
and the previous reports studying the SOCS family in human
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liver disease. In the next paper, Dr. H. Tsutsui and her
colleagues summarize their studies that have identified TLR-
mediated IL-1β and IL-18 processing through activation of
the inflammasome in the liver. In the fifth paper, Dr. M. Gale
Jr. and his research group have uncovered the intracellular
innate immune signaling against HCV infection. He and
his colleague review the biological host response against
HCV and how HCV escapes from RIG-I-dependent innate
immune response for sustaining HCV infection.
The next sections address specific liver functions and
diseases. In the sixth paper, Dr. K. Machida summarizes
his previous work studying the association between HCV
and TLR4, and now his research is extending to the study
of HCV-mediated tumorigenesis in which cancer stem cells
could be crucial, and its possible cross-talk with alcohol. In
the following paper, Drs. Y. Iimuro and J. Fujimoto review
molecular mechanisms triggering liver regeneration after
partial hepatectomy. TNF-α and IL-6 are known to trigger
liver regeneration. They discuss the role of TLR/MyD88-
dependent signaling upstream TNF-α and IL-6 in liver
regeneration. They also describe the possible interaction
between NF-κB and JNK/c-Jun in liver regeneration. In the
eighth paper, cutting-edge research on TLRs in ischemia-
reperfusion injury has been done by the research group
led by Drs. A. Tsung and T. Billiar. They were the first to
identify that HMGB-1 released from damaged cells is an
endogenous ligand for TLR4 and that HMGB-1 triggers
ischemia-reperfusion liver injury through TLR4. The inter-
action between alcoholic liver disease and TLR signaling has
been studied for more than ten years. Dr. Thurman’s research
group demonstrated the role of TLR4 and gut microflora
in alcoholic liver disease using intragastric ethanol infusion
model. Currently, Dr. Szabo’s research group advances the
studies in this field. In ninth paper, she and her colleagues
concisely summarize the importance of TLRs and adaptor
molecules in alcoholic liver disease. The importance of TLRs
has been demonstrated not only in alcoholic liver disease,
but also in nonalcoholic liver disease. In the tenth paper,
Drs. K. Miura and D. Brenner outline the recent advance of
TLRs and nonalcoholic liver disease. In the next paper, Dr. E.
Seki and his colleagues have demonstrated the interaction of
the TLR4 and TGF-β signaling pathways in hepatic stellate
cells. They discuss the signaling of TLR4 and the other
TLRs in the activation of hepatic stellate cells and liver
fibrosis. The proportion of NK cells and NKT cells in liver
is much greater than that in the other organs. These cells
are major targets for TLR3 ligand poly I:C. Dr B. Gao’s
research group is focsing on this signaling in liver physiology
and in liver disease models. In the twelfth paper, they
summarize their recent findings of TLR3 signaling in liver
disease. In the following paper, Dr. S. Maeda demonstrated
the role of hepatocyte NF-κB, JNK, and MyD88 using an
animal model of liver cancer. He discusses the role of TLRs,
NF-κB, and JNK signaling in liver cancer. Modification of
gut microflora might be a potential target for liver disease
because of the unique anatomical association between the
liver and intestines. In the fourteenth paper, Dr. I. Hines
and his colleague review the molecular mechanisms by
which gut microflora contributes to the development of liver
disease. In the fifteenth paper, Drs. T. Hayashi and K. Suzuki
highlight their previous work on TLR4-mediated expression
of protein S and C4b binding protein in the liver. The role
of TLR4 signaling in the development of insulin resistance
is intensively being studied. In the last paper, Drs. J. J. Kim
and D. D. Sears summarize the recent advances in the field of
innate immunity and insulin resistance.
In this special issue, we gather 16 articles highlighting
our current knowledge of TLR signaling in the liver. TLR
signaling induces the initial response in inflammation. This
response may then induce intestinal barrier destruction and
subsequent bacterial translocation as well as the release
of endogenous ligands from damaged cells. These events
could cause a secondary activation of TLR signaling. Thus,
targeting either the initial or secondary responses induced
by TLR signaling might become eﬀective therapy for liver
diseases. While we could not include discussion of the
potential of TLR agonists for the therapy of liver disease
in this special issue due to page limitations, this might
be an attractive approach for some liver diseases, such as
liver fibrosis and cancer. We trust that the articles in this
special issue will help in understanding the TLR-related
mechanisms underlying liver diseases and stimulate new
ideas for targeting TLRs and their signaling pathways to
develop new therapeutic applications for liver disease.
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